Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y6M9

UPID:
NDUB9_HUMAN

ALTERNATIVE NAMES:
Complex I-B22; LYR motif-containing protein 3; NADH-ubiquinone oxidoreductase B22 subunit

ALTERNATIVE UPACC:
Q9Y6M9; B2R8M6; Q9UQE8

BACKGROUND:
The protein NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9, known alternatively as Complex I-B22, LYR motif-containing protein 3, or NADH-ubiquinone oxidoreductase B22 subunit, is integral to mitochondrial function. It is involved in electron transfer within the mitochondrial respiratory chain, specifically from NADH to ubiquinone, though it is not directly involved in catalysis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 could open doors to potential therapeutic strategies for treating Mitochondrial complex I deficiency, nuclear type 24, and related mitochondrial disorders. These conditions range in severity and include a spectrum of symptoms, underscoring the importance of targeted research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.